Program
Test Product HY07121
A development code. Also written as “Test Product HY07121 for Injection (Subcutaneous)”.
Its studies are led by Sichuan Huiyu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Huiyu Pharmaceutical | 22 open or running | phase 2since Oct 10, 2024 | Oct 10, 2024 | May 26, 2027phase 2 · NCT06639256 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2024First study: phase 2 study in SafetyFirst studyNCT06639256 · 258 planned · China
- Aug 24, 2026Phase 2 study in SafetyNCT07789327 · 254 planned
- Oct 13, 2026Primary completion moved from 2026-05 to 2027-05-26Date moved laterphase 2 · +12 months · NCT06639256
Ahead
- May 26, 2027Primary completion: phase 2 study in SafetyNCT06639256
- Apr 2028Primary completion: phase 2 study in SafetyNCT07789327
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07789327Safety | 2 | Not yet recruiting | Apr 2028 | 254 |
| NCT06639256Safety · China | 2 | Recruiting | May 26, 2027 | 258 |
How it is read
Names in the registry
- “Test Product HY07121 for Injection (Subcutaneous)”, 2 entries
- “Test Product HY07121”, 1 entry
Codes read as this program: HY07121.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.